Product Information

ImprimisRx® Product Information

ImprimisRx specializes in compounding customized medications to meet unique patient needs. As with all compounded medications, dosages may be customized to meet the individual needs of a patient. Only a prescribing physician may determine the appropriate use for their patient for an ImprimisRx compounded medication.

Compounded medications, made for the specific needs of a patient, are by their nature, not reviewed nor approved by the U.S. Food and Drug Administration (“FDA”).

All ImprimisRx facilities, where our compounded medications are produced, are inspected by FDA.

All active pharmaceutical ingredients contained in ImprimisRx’s compounded medications are obtained from FDA-registered entities.

When applicable, ImprimisRx compounded medications include components of FDA-approved drugs, as required under federal law.

ImprimisRx compounded medications may be ordered by a prescribing physician only when there is not a sufficient commercially available drug to meet a patient’s clinical need. Prescribing physicians may contact ImprimisRx’s pharmacists to discuss whether one of our compounded medications may be suitable for the clinical needs of a patient.

Regardless of a patient’s ability to afford an FDA-approved commercially available medication, FDA guidance prohibits ImprimisRx’s from copying any commercially available FDA-approved product.

ImprimisRx’s formulations are intended for professional use only.

Tri-Moxi® (Triamcinolone/Moxifloxacin) - Potential Ingredient Risks

(Triamcinolone acetonide 15mg and Moxifloxacin hydrochloride 1mg/mL)

May be customized.

Triamcinolone Acetonide
(15mg/mL)

Moxifloxacin HCl
(1mg/mL)

Possible Indications

Postoperative Ophthalmic Inflammation
Sympathetic Ophthalmia
Diffuse Posterior Uveitis
Allergic Corneal Margin Ulcer
Iritis and Keratitis
Optic Neuritis

Bacterial Conjunctivitis

Field Experience with Regards to
Temporary Visual Impairment

Following intraocular administration of Triamcinolone Acetonide Suspension, it has been reported that visual acuity and “floaters” can take several hours; up to 36 hours to clear and in rare cases, up to 48 hours. Because of the nature of a suspension, which includes particles suspended in a vehicle, it is likely to affect the visual field for a period of time and consequently, patients should be appropriately counseled prior to use. The patient is encouraged to sit upright for 6 hours.

Possible Adverse Effects

Anaphylactoid Shock
Blindness
Cataract
Corneal Perforation
Cortical Cataract
Conjunctival Hemorrhage
Eye Pain, Infection, Irritation Pruritus
Abnormal Sensation in Eyes
Abnormal Sensory Symptoms
Edema
Bleeding at Injection Site
Glaucoma
Hypertension
Hypopyon
Increased Intraocular Pressure
Increased Lacrimation
Vitreous Detachment
Vitreous Opacity
Wound Healing Impairment

Conjunctival Irritation
Fever
Eye Irritation
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Dyspnea
Facial Edema
Fungal Superinfection
Laryngeal Edema
Loss of Consciousness
Pharyngeal Edema
Pruritus
Superinfection
Urticaria
Pigment Dispersion Syndrome

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake well before use

Store upright in original bottle

Dex-Moxi® (Dexamethasone/Moxifloxacin) - Potential Ingredient Risks

(Dexamethasone 1mg and Moxifloxacin hydrochloride 5mg/mL)

May be customized.

Dexamethasone Sodium Phosphate
(1mg/mL)

Moxifloxacin HCl
(5mg/mL)

Possible Indications

Post-Surgical Inflammation
Allergic Conjunctivitis
Inflammation of Anterior Segment of Eye
Keratitis, Optic Neuritis, Iritis
Sympathetic Ophthalmia

Bacterial Conjunctivitis

Possible Adverse Effects

Conjunctival Irritation
Burning and Stinging Sensation
Fever
Eye Irritation and Infection
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Blindness
Post-Injection Flare
Wound Healing Suppression
Anaphylaxis
Corneal Perforation
Headache
Subcapsular Posterior Cataract
Ocular Hypertension
Optic Nerve Damage
Visual Field Defect

Conjunctival Irritation
Fever
Eye Irritation
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Dyspnea
Facial Edema
Fungal Superinfection
Laryngeal Edema
Loss of Consciousness
Pharyngeal Edema
Pruritus
Superinfection
Urticaria
Pigment Dispersion Syndrome

Potential Contraindications/Precautions

Infants and patients less than 12 years of age
Lactation
Pregnancy

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

For Professional use only

Dex-Moxi-Ketor® (Dexamethasone/Moxifloxacin/Ketorolac) - Potential Ingredient Risks

(Dexamethasone 1mg, Moxifloxacin hydrochloride 0.5mg, and Ketorolac 0.4mg/mL)

May be customized.

Dexamethasone Sodium Phosphate
(1mg/mL)

Moxifloxacin HCl
(0.5mg/mL)

Ketorolac Tromethamine
(0.4mg/mL)

Possible Indications

Postoperative Inflammation
Allergic Conjunctivitis
Inflammation of Anterior Segment of Eye
Keratitis, Optic Neuritis, Iritis
Sympathetic Ophthalmia

Bacterial Conjunctivitis

Postoperative Eye Pain
Transient Burning and Stinging in the Eyes

Possible Adverse Effects

Conjunctival Irritation
Burning and Stinging Sensation
Fever
Eye Irritation and Infection
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Blindness
Post-Injection Flare
Wound Healing Suppression
Anaphylaxis
Corneal Perforation
Headache
Subcapsular Posterior Cataract
Ocular Hypertension
Optic Nerve Damage
Visual Field Defect

Conjunctival Irritation
Fever
Eye Irritation
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Dyspnea
Facial Edema
Fungal Superinfection
Laryngeal Edema
Loss of Consciousness
Pharyngeal Edema
Pruritus
Superinfection
Urticaria
Pigment Dispersion Syndrome

Burning Sensation of Eyes
Stinging of Eyes
Conjunctival Hyperemia
Corneal Edema
Corneal Erosion
Corneal Infiltrates
Corneal Perforation
Corneal Thinning
Eye Pain and Irritation
Headache
Hypercreativity Reaction
Iritis
Ocular Edema
Ophthalmic Inflammation
Superficial Eye Infection
Superficial Keratitis
Tissue Damage

Potential Contraindications/Precautions

Infants and patients less than
12 Years of age
Lactation
Pregnancy

Infants
Lactation
Pregnancy

Infants and patients less than
12 Years of age
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

For professional use only

Moxifloxacin HCl - Potential Ingredient Risks

(Moxifloxacin hydrochloride)

May be customized.

Moxifloxacin HCl

Possible Indications

Bacterial Conjunctivitis

Possible Adverse Effects

Conjunctival Irritation
Fever
Eye Irritation
Airway Obstruction
Anaphylaxis
Angioedema
Circulatory Shock
Dyspnea
Facial Edema
Fungal Superinfection
Laryngeal Edema
Loss of Consciousness
Pharyngeal Edema
Pruritus
Superinfection
Urticaria
Pigment Dispersion Syndrome

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle.
Protect from light.
For professional use only.

Hyaluronidase - Potential Ingredient Risks

(Hyaluronidase 175 units/mL)

May be customized.

Hyaluronidase
(175 units/mL)

Possible Indications

Adjunct to local anesthetic blocks for ophthalmic surgery; Adjunct to increase the dispersion and absorption of other injected drugs; adjunct in subcutaneous hydration therapy

Possible Adverse Effects

Local injection-site reactions
(erythema and pain)
Edema (when administered SQ)
Hypersensitivity
Increased intraocular pressure
Eye pain
Reduced visual acuity
Can enhance adverse reactions of
co-administered drugs

Potential Contraindications/Precautions

Lactation
Pregnancy
Patients with bee sting
allergy

Storage

Keep frozen until use.
-25°C to -10°C (-13°F to 14°F)

Auxillary Labeling

Store upright in original bottle.
Protect from light.
For professional use only.

Lidocaine 1% - Potential Ingredient Risks

(Lidocaine 1%)

May be customized.

Lidocaine

(1%)

Possible Indications

To provide local anesthesia during ophthalmic procedures.

Possible Adverse Effects

Conjunctival Hyperemia
Corneal Epithelial Changes
Burning upon administration
Headache

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light.
For professional use only.

Lidocaine 2% - Potential Ingredient Risks

(Lidocaine 2%)

May be customized.

Lidocaine

(2%)

Possible Indications

To provide local anesthesia during ophthalmic procedures.

Possible Adverse Effects

Conjunctival Hyperemia
Corneal Epithelial Changes
Burning upon administration
Headache

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light.
For professional use only.

Epi-Lido (Lidocaine hydrochloride/Epinephrine in BSS) PF/SF - Potential Ingredient Risks

(Lidocaine hydrochloride/Epinephrine in BSS (PF/SF) 0.75/0.025%)

May be customized.

Epinephrine HCl
(0.025%)

Lidocaine HCl
(0.75%)

Possible Indications

Intraoperative Mydriasis
Open-Angle Glaucoma
Hemorrhage During Ocular Surgery

Ocular Anesthesia

Possible Adverse Effects

Increased Intraocular pressure
Hypertension

Conjunctival Hyperemia
Corneal Epithelial Changes
Headache

Potential Contraindications/Precautions

Lactation
Pregnancy

Infants
Lactation
Pregnancy

Storage

Store Refrigerated for up to 120 days

2-8°C

Auxillary Labeling

Do not Refreeze

Store upright in original bottles. Protect from light. For professional use only.

Phenyl-Lido (Phenylephrine hydrochloride/Lidocaine hydrochloride) PF/SF - Potential Ingredient Risks

(Phenylephrine hydrochloride/Lidocaine hydrochloride (PF/SF) 1.5/1%)

May be customized.

Phenylephrine HCl
(1.5%)

Lidocaine HCl
(1%)

Possible Indications

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Ocular Anesthesia

Possible Adverse Effects

Increased Intraocular pressure
Hypertension

Conjunctival Hyperemia
Corneal Epithelial Changes
Headache

Potential Contraindications/Precautions

Lactation
Pregnancy

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

For professional use only.

Mydriatic 2 (Tropicamide/Phenylephrine) - Potential Ingredient Risks

(Tropicamide/Phenylephrine hydrochloride, 1/2.5%)

May be customized.

Tropicamide
(1%)

Phenylephrine HCl
(2.5%)

Possible Indications

Cycloplegia
Mydriasis

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Possible Adverse Effects

Blurred Vision
Cardiorespiratory Arrest
Headache
Hypersensitivity Reaction
Increased Intraocular Pressure
Muscle Rigidity
Nausea
Pallor
Photophobia
Psychotic Reaction
Superficial Punctate Keratitis
Tachycardia
Transient Burning or Stinging in the Eyes
Vomiting
Xerostomia

Acute Keratitis
Acute Myocardial Infarction
Allergic Conjunctivitis
Blurred Vision
Dermatitis
Diaphoresis
Dizziness
Eye Irritation
Headache
Hypertension
Lacrimation
Pallor
Photophobia
Pigment Granules Liberation from the Iris
Subarachnoid Hemorrhage
Syncope
Tachycardia
Tremor

Potential Contraindications/Precautions

Patients less than 12 years of age
Lactation
Pregnancy

Neonates and patients less than 12 years of age
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

For professional use only.

Mydriatic 3* (Tropicamide/Cyclopentolate/Phenylephrine) - Potential Ingredient Risks

(Tropicamide 1%, Cyclopentolate 1%, and Phenylephrine hydrochloride 2.5%)

May be customized.

Tropicamide
(1%)

Cyclopentolate
(1%)

Phenylephrine HCl
(2.5%)

Possible Indications

Cycloplegia
Mydriasis

Cycloplegia
Mydriasis
Posterior Synechiae
Uveitis

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Possible Adverse Effects

Blurred Vision
Cardiorespiratory Arrest
Headache
Hypersensitivity Reaction
Increased Intraocular Pressure
Muscle Rigidity
Nausea
Pallor
Photophobia
Psychotic Reaction
Superficial Punctate Keratitis
Tachycardia
Transient Burning or Stinging in the Eyes
Vomiting
Xerostomia

Blurred Vision
Burning Sensation
Coma
Death
Disorientation
Dry Secretions
Eye Irritation
Hallucination
Hyperactive Behavior
Hyperpyrexia
Hypertension
Hyperhidrosis
Increased Intraocular Pressure
Photophobia
Psychotic Reaction
Restlessness
Seizure
Superficial Punctate Keratitis
Tachycardia
Urinary Retention
Vasodilation
Xerostomia

Acute Keratitis
Acute Myocardial Infarction
Allergic Conjunctivitis
Blurred Vision
Dermatitis
Diaphoresis
Dizziness
Eye Irritation
Headache
Hypertension
Lacrimation
Pallor
Photophobia
Pigment Granules Liberation from the Iris
Subarachnoid Hemorrhage
Syncope
Tachycardia
Tremor
Ventricular Premature contractions

Potential Contraindications/Precautions

Patients less than 12 years of age
Lactation
Pregnancy

Infants

Neonates and patients less than 12 years of age
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

For professional use only

Mydriatic 4*(Tropicamide/Proparacaine/Phenylephrine/Ketorolac) - Potential Ingredient Risks

(Tropicamide 1%, Proparacaine 0.5%, Phenylephrine 2.5%, and Ketorolac 0.5%)

May be customized.

Tropicamide
(1%)

Proparacaine HCl
(0.5%)

Phenylephrine HCl
(2.5%)

Ketorolac Tromethamine
(0.5%)

Possible Indications

Cycloplegia
Mydriasis

Ocular Anesthesia

Mydriasis
Posterior Synechiae
Uveitis with Posterior Synechiae

Cystoid Macular Edema
Miosis
Postoperative Eye Pain
Postoperative Ophthalmic Inflammation
Seasonal Allergic Conjunctivitis
Transient Burning or Stinging in the Eyes

Possible Adverse Effects

Blurred Vision
Cardiorespiratory Arrest
Headache
Hypersensitivity Reaction
Increased Intraocular Pressure
Muscle Rigidity
Nausea
Pallor
Photophobia
Psychotic Reaction
Superficial Punctate Keratitis
Tachycardia
Transient Burning or Stinging in the Eyes
Vomiting
Xerostomia

Blurred Vision
Stinging of the Eyes
Hypersensitivity Reaction

Acute Keratitis
Acute Myocardial Infarction
Allergic Conjunctivitis
Blurred Vision
Dermatitis
Diaphoresis
Dizziness
Eye Irritation
Headache
Hypertension
Lacrimation
Pallor
Photophobia
Pigment Granules Liberation from the Iris
Subarachnoid Hemorrhage
Syncope
Tachycardia
Tremor
Ventricular Premature contractions

Burning Sensation of Eyes
Stinging of Eyes
Eye Irritation
Hypersensitivity
Pruritus and Skin Rash
Superficial Keratitis
Superficial Bacterial Eye Infection
Conjunctival Hyperemia
Corneal Edema
Corneal Erosion
Corneal Infiltrates
Corneal Perforation
Corneal Thinning
Eye Pain
Headache
Iritis
Ocular Edema
Superficial Keratitis
Tissue Damage

Potential Contraindications/

Precautions

Patients less than 12 Years of age
Lactation
Pregnancy

Infants
Lactation
Pregnancy

Neonates and patients less than
12 years of age
Lactation
Pregnancy

Patients less than 3 years of age
Lactation
Pregnancy
Child bearing aged females

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Protect from light

For professional use only

MKO Melt® (Midazolam, Ketamine HCl, Ondansetron) - Potential Ingredient Risks

(Midazolam 3mg, Ketamine HCl 25mg, Ondansetron 2mg)

May be customized.

Midazolam
(3mg)

Ketamine HCl
(25mg)

Ondansetron
(2mg)

Possible Indications

Surgical Sedation
Amnesia
Anxiety

Surgical Anesthesia
Induction of General Anesthesia

Postoperative Nausea and Vomiting
Cancer Chemotherapy-Induced Nausea and Vomiting

Possible Adverse Effects

Hypoxemia
Nausea and Vomiting
Agitation
Airway Obstruction
Bradycardia
Hypoxia
Laryngospasm
Respiratory Depression
Rhonchi
Sedation
Skin Rach
Cardia Arrest
Respiratory Arrest

Airway Obstruction
Anaphylaxis
Anxiety
Apnea
Bradycardia
Cardia Arrhythmia
Confusion
Disorientation
Dysphoria
Hallucination
Hypotension
Insomnia
Nausea
Nystagmus
Psychotic Reaction
Respiratory Depression
Skin Rash
Tonic Clonic Epilepsy
Vomiting

Headache and Malaise
Sedation
Wound Healing Impairment
Anxiety
Bradycardia
Constipation
Diarrhea
Dizziness
Fever
Gynecologic Disease
Hypotension
Hypoxia
Pruritus
Shivering
Urinary Retention
Skin Rach
Anaphylaxis
Chest Pail
Dyspnea
Laryngeal Edema

Potential Contraindications/Precautions

Infants less than 6 months of age
Lactation
Pregnancy

Lactation
Pregnancy

Infants less than 6 months of age
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

For professional use only

Lat* (Latanoprost) PF - Potential Ingredient Risks

(Latanoprost 0.005%)

May be customized.

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma

Possible Adverse Effects

Iris pigmentation changes
Eyelid skin darkening
Eyelash changes (increased length, thickness,
pigmentation and number of lashes)
Iritis/uveitis
Macular edema, including cystoid macular
edema
Foreign body sensation
Punctate keratitis
Stinging
Conjunctival hyperemia
Blurred vision
Itching
Burning
Increased pigmentation of the iris
Excessive tearing
Eyelid discomfort/pain
Dry eye
Eye pain
Eyelid margin crusting

Erythema of the eye lid

Photophobia

Potential Contraindications/Precautions

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration.
2°C to 8°C (36°F to 46°F)
Protect from light.

Auxillary Labeling

For professional use only.
Store upright in original bottle.

Dor* (Dorzolamide) PF - Potential Ingredient Risks

(Dorzolamide 2%)

May be customized.

Dorzolamide
(2%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning, stinging, or discomfort
immediately following ocular administration
Bitter taste
Superficial punctate keratitis
Ocular allergic reaction
Conjunctivitis and lid reactions
Blurred vision
Eye redness
Tearing
Dryness
Photophobia
Headache
Nausea
Asthenia/fatigue
Skin rashes
Urolithiasis
Iridocyclitis

Potential Contraindications/Precautions

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Storage

Store at room temperature.
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light.
Store upright in original bottle

Brim-Dor®* (Brimonidine Tartrate, Dorzolamide) PF - Potential Ingredient Risks

(Brimonidine Tartrate 0.15%, Dorzolamide 2%)

May be customized. customized.

Brimonidine Tartrate
(0.15%)

Dorzolamide
(2%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Oral dryness
Ocular hyperemia,
Burning and Stinging on Instillation
Headache
Blurred vision
Foreign body sensation
Fatigue/drowsiness
Conjunctival follicles
Ocular allergic reactions
Ocular pruritis
Corneal staining/erosion
Photophobia
Eyelid erythema
Ocular ache/pain
Upper respiratory symptoms
Dizziness
Blepharitis, ocular irritation
Lid crusting
Conjunctival hemorrhaging
Abnormal taste, insomnia, depression,
hypertension, anxiety, palpitations/
arrhythmias, nasal dryness and syncope

Ocular burning, stinging, or discomfort
immediately following ocular administration
Bitter taste
Superficial punctate keratitis
Ocular allergic reaction
Conjunctivitis and lid reactions
Blurred vision
Eye redness
Tearing
Dryness
Photophobia
Headache
Nausea
Asthenia/fatigue
Skin rashes
Urolithiasis
Iridocyclitis

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Concomitant MAO Inhibitor Therapy

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle.

Protect from light.

Tim-Lat®* (Timolol Maleate, Latanoprost) PF - Potential Ingredient Risks

(Timolol Maleate 0.5%, Latanoprost 0.005%)

May be customized. customized.

Timolol Maleate
(0.5%)

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning/stinging on instillation
Dry eyes
Itching
Foreign body sensation
Discomfort in the eye
Eyelid erythema
Conjunctival injection
Headache
Eye pain
Epiphora
Photophobia
Blurred or abnormal vision
Corneal fluorescein staining
Keratitis
Blepharitis
Cataract
Cardiac arrythmia, palpitation, bradycardia,
Syncope, heart block, cerebral vascular
accident, cerebral ischemia, cardiac failure and
cardiac arrest

Iris pigmentation changes
Eyelid skin darkening
Eyelash changes (increased length, thickness,
pigmentation and number of lashes)
Iritis/uveitis
Macular edema, including cystoid macular
edema
Foreign body sensation
Punctate keratitis
Stinging
Conjunctival hyperemia
Blurred vision
Itching
Burning
Increased pigmentation of the iris
Excessive tearing
Eyelid discomfort/pain
Dry eye
Eye pain
Eyelid margin crusting
Erythema of the eyelid
Photophobia

Potential Contraindications/Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration.
Protect from light.

2°C to 8°C (36°F to 46°F)

Auxillary Labeling

For professional use only.

Store upright in original bottle.

Tim-Dor-Lat®* (Timolol Maleate, Dorzolamide, Latanoprost) PF - Potential Ingredient Risks

(Timolol Maleate 0.5%, Dorzolamide 2%, and Latanoprost 0.005%)

May be customized.

Timolol Maleate
(0.5%)

Dorzolamide
(2%)

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning/stinging on instillation
Dry eyes
Itching
Foreign body sensation
Discomfort in the eye
Eyelid erythema
Conjunctival injection
Headache
Eye pain
Epiphora
Photophobia
Blurred or abnormal vision
Corneal fluorescein staining
Keratitis
Blepharitis
Cataract
Cardiac arrythmia, palpitation, bradycardia,
Syncope, heart block, cerebral vascular
accident, cerebral ischemia, cardiac failure and
cardiac arrest

Ocular burning, stinging, or discomfort
immediately following ocular administration
Bitter taste
Superficial punctate keratitis
Ocular allergic reaction
Conjunctivitis and lid reactions
Blurred vision
Eye redness
Tearing
Dryness
Photophobia
Headache
Nausea
Asthenia/fatigue
Skin rashes
Urolithiasis

Iris pigmentation changes
Eyelid skin darkening
Eyelash changes (increased length, thickness,
pigmentation and number of lashes)
Iritis/uveitis
Macular edema, including cystoid macular
edema
Foreign body sensation
Punctate keratitis
Stinging
Conjunctival hyperemia
Blurred vision
Itching
Burning
Increased pigmentation of the iris
Excessive tearing
Eyelid discomfort/pain
Dry eye
Eye pain
Eyelid margin crusting
Erythema of the yelid
Photophobia

Potential Contraindications/Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration

2°C to 8°C (36°F to 46°F)

Protect from light.

Auxillary Labeling

For professional use only.

Store upright in original bottle

Tim-Brim-Dor®* (Timolol Maleate, Brimonidine Tartrate, Dorzolamide) PF - Potential Ingredient Risks

(Timolol Maleate 0.5%, Brimonidine Tartrate 0.15%, and Dorzolamide 2%)

May be customized.

Timolol Maleate
(0.5%)

Brimonidine Tartrate
(0.15%)

Dorzolamide
(2%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning/stinging on instillation
Dry eyes
Itching
Foreign body sensation
Discomfort in the eye
Eyelid erythema
Conjunctival injection
Headache
Eye pain
Epiphora
Photophobia
Blurred or abnormal vision
Corneal fluorescein staining
Keratitis
Blepharitis
Cataract
Cardiac arrythmia, palpitation, bradycardia,
Syncope, heart block, cerebral vascular
accident, cerebral ischemia, cardiac failure and
cardiac arrest

Oral dryness
Ocular hyperemia,
Burning and Stinging on Instillation
Headache
Blurred vision
Foreign body sensation
Fatigue/drowsiness
Conjunctival follicles
Ocular allergic reactions
Ocular pruritis
Corneal staining/erosion
Photophobia
Eyelid erythema
Ocular ache/pain
Upper respiratory symptoms
Dizziness
Blepharitis, ocular irritation
Lid crusting
Conjunctival hemorrhaging
Abnormal taste, insomnia, depression,
hypertension, anxiety, palpitations/
arrhythmias, nasal dryness and syncope

Ocular burning, stinging, or discomfort
immediately following ocular administration
Bitter taste
Superficial punctate keratitis
Ocular allergic reaction
Conjunctivitis and lid reactions
Blurred vision
Eye redness
Tearing
Dryness
Photophobia
Headache
Nausea
Asthenia/fatigue
Skin rashes
Urolithiasis
Iridocyclitis

Potential Contraindications/Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Infants
Lactation
Pregnancy
Concomitant MAO Inhibitor Therapy

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Storage

Store at room temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

For professional use only.

Store upright in original bottle

Protect from light.

Tim-Brim-Dor-Lat®* (Timolol Maleate, Brimonidine Tartrate, Dorzolamide, Latanoprost) PF - Potential Ingredient Risks

(Timolol Maleate 0.5%, Brimonidine Tartrate 0.15%, Dorzolamide 2%, Latanoprost 0.005%) PF

May be customized.

Timolol Maleate
(0.5%)

Brimonidine Tartrate
(0.15%)

Dorzolamide
(2%)

Latanoprost
(0.005%)

Possible Indications

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Treatment of elevated intraocular
pressure in patients with ocular
hypertension or open-angle glaucoma

Possible Adverse Effects

Ocular burning/stinging on instillation
Dry eyes
Itching
Foreign body sensation
Discomfort in the eye
Eyelid erythema
Conjunctival injection
Headache
Eye pain
Epiphora
Photophobia
Blurred or abnormal vision
Corneal fluorescein staining
Keratitis
Blepharitis
Cataract
Cardiac arrythmia, palpitation, bradycardia,
Syncope, heart block, cerebral vascular accident,
cerebral ischemia, cardiac failure and cardiac arrest

Oral dryness
Ocular hyperemia,
Burning and Stinging on Instillation
Headache
Blurred vision
Foreign body sensation
Fatigue/drowsiness
Conjunctival follicles
Ocular allergic reactions
Ocular pruritis
Corneal staining/erosion
Photophobia
Eyelid erythema
Ocular ache/pain
Upper respiratory symptoms
Dizziness
Blepharitis, ocular irritation
Lid crusting
Conjunctival hemorrhaging
Abnormal taste, insomnia, depression,
hypertension, anxiety, palpitations/
arrhythmias, nasal dryness and syncope

Ocular burning, stinging, or discomfort
immediately following ocular administration
Bitter taste
Superficial punctate keratitis
Ocular allergic reaction
Conjunctivitis and lid reactions
Blurred vision
Eye redness
Tearing
Dryness
Photophobia
Headache
Nausea
Asthenia/fatigue
Skin rashes
Urolithiasis
Iridocyclitis

Iris pigmentation changes
Eyelid skin darkening
Eyelash changes (increased length, thickness,
pigmentation and number of lashes)
Iritis/uveitis
Macular edema, including cystoid macular
edema
Foreign body sensation
Punctate keratitis
Stinging
Conjunctival hyperemia
Blurred vision
Itching
Burning
Increased pigmentation of the iris
Excessive tearing
Eyelid discomfort/pain
Dry eye
Eye pain
Eyelid margin crusting
Erythema of the eye lid
Photophobia

Potential Contraindications/
Precautions

Patients Less than 12 Years
Lactation
Pregnancy
Bronchial Asthma or History Of.
Sinus Bradycardia, Second or Third Degree
Atrioventricular Block; Overt Heart Failure;
Cardiogenic Shock.

Infants
Lactation
Pregnancy
Concomitant MAO Inhibitor Therapy

Neonates and Patients Less than 12 Years
Lactation
Pregnancy

Patients Less than 3 Years
Lactation
Pregnancy
Child Bearing Aged Females

Storage

Store under refrigeration

2°C to 8°C (36°F to 46°F)

Auxillary Labeling

For professional use only.

Store upright in original bottle

Protect from light

Pred-Gati-Brom®* Suspension (Prednisolone Acetate, Gatifloxacin, Bromfenac) - Potential Ingredient Risks

(Prednisolone Acetate 1%, Gatifloxacin 0.5%, Bromfenac 0.075%)

May be customized.

Prednisolone Acetate
(1%)

Gatifloxacin
(0.5%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Accommodation Disturbance
Anterior Uveitis
Blepharitis
Conjunctival Hyperemia
Conjunctivitis
Corneal Perforation or Ulcer
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Visual Field Defect
Wound Healing Impairment

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis

Abnormal Sensation in Eyes
Anaphylaxis
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stinging Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

Pred-Gati-Brom®* Solution (Prednisolone Phosphate, Gatifloxacin, Bromfenac) - Potential Ingredient Risks

(Prednisolone Phosphate 1%, Gatifloxacin 0.5%, Bromfenac 0.075%)

May be customized.

Prednisolone Phosphate
(1%)

Gatifloxacin
(0.5%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Burning or Stinging Sensation
Accommodation Disturbance
Conjunctival Hyperemia
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Subscapular Posterior Cataract
Visual Field Defect
Wound Healing Impairment
Corneal Ulcer
Viral Infection

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis

Abnormal Sensation in Eyes
Anaphylaxis
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stinging Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light

Store upright in original bottle

Pred-Moxi-Nepaf® (Prednisolone Acetate, Moxifloxacin, Nepafenac) - Potential Ingredient Risks

(Prednisolone Acetate 1%, Moxifloxacin 0.5%, Nepafenac 0.1%)

May be customized.

Prednisolone Acetate
(1%)

Moxifloxacin
(0.5%)

Nepafenac
(0.1%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Accommodation Disturbance
Anterior Uveitis
Blepharitis
Conjunctival Hyperemia
Conjunctivitis
Corneal Perforation or Ulcer
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Visual Field Defect
Wound Healing Impairment

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis
Pyrexia
Subconjunctival Hemorrhage
Tearing
Hypersensitivity Reaction

Abnormal Sensation in Eyes
Increased Intraocular Pressure
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stinging Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia (bleeding disorders)

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Store upright in original bottle.

Protect from light.

Pred-Moxi® (Prednisolone Acetate, Moxifloxacin) - Potential Ingredient Risks

(Prednisolone Acetate 1%, and Moxifloxacin 0.5%)

May be customized.

Prednisolone Acetate
(1%)

Moxifloxacin
(0.5%)

Possible Indications

Postoperative Ophthalmic
Inflammation
Postoperative Eye Pain

Bacterial Conjunctivitis

Possible Adverse Effects

Accommodation Disturbance
Anterior Uveitis
Blepharitis
Conjunctival Hyperemia
Conjunctivitis
Corneal Perforation or Ulcer
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Visual Field Defect
Wound Healing Impairment

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis
Pyrexia
Subconjunctival Hemorrhage
Tearing
Hypersensitivity Reaction

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Store upright in original bottle

Pred-Gati®* (Prednisolone Acetate, Gatifloxacin) - Potential Ingredient Risks

(Prednisolone Acetate 1%, and Gatifloxacin 0.5%)

May be customized.

Prednisolone Acetate
(1%)

Gatifloxacin
(0.5%)

Possible Indications

Postoperative Ophthalmic
Inflammation

Bacterial Conjunctivitis

Possible Adverse Effects

Accommodation Disturbance
Anterior Uveitis
Blepharitis
Conjunctival Hyperemia
Conjunctivitis
Corneal Perforation or Ulcer
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Visual Field Defect
Wound Healing Impairment

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Protect from light.

Store upright in original bottle

Pred-Brom®* (Prednisolone Phosphate, Bromfenac) - Potential Ingredient Risks

(Prednisolone Phosphate 1%, and Bromfenac 0.075%)

May be customized.

Prednisolone Phosphate
(1%)

Bromfenac
(0.075%)

Possible Indications

Postoperative Ophthalmic Inflammation
Postoperative Eye Pain

Postoperative Ophthalmic Inflammation
Postoperative Ophthalmic Pain

Possible Adverse Effects

Burning or Stinging Sensation
Accommodation Disturbance
Conjunctival Hyperemia
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Subscapular Posterior Cataract
Visual Field Defect
Wound Healing Impairment
Corneal Ulcer
Viral Infection

Abnormal Sensation in Eyes
Anaphylaxis
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stinging Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Protect from light.

Store upright in original bottle

Pred-Nepaf® (Prednisolone Acetate, Nepafenac) - Potential Ingredient Risks

(Prednisolone Acetate 1%, and Nepafenac 0.01%)

May be customized.

Prednisolone Acetate
(1%)

Nepafenac
(0.01%)

Possible Indications

Postoperative Ophthalmic
Inflammation
Postoperative Eye Pain

Postoperative Ophthalmic
Inflammation
Postoperative Eye Pain

Possible Adverse Effects

Accommodation Disturbance
Anterior Uveitis
Blepharitis
Conjunctival Hyperemia
Conjunctivitis
Corneal Perforation or Ulcer
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Visual Field Defect
Wound Healing Impairment

Abnormal Sensation in Eyes
Anaphylaxis
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stinging Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy
Cataract
Eye Infection
Increased Intraocular Pressure

Lactation
Pediatric Patients
Pregnancy
Corneal Disease
Thrombocytopenia

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake Well Before Use!

Prednisolone Acetate - Potential Ingredient Risks

(Prednisolone Acetate 1%)

May be customized.

Prednisolone Acetate
(1%)

Possible Indications

Postoperative Inflammation
Blepharitis
Allergic Conjunctivitis
Catarrhal Corneal Ulcer
Conjunctival Infection
Corneal Injury
Keratoconjunctivitis
Superficial Keratitis
Vernal Conjunctivitis

Possible Adverse Effects

Accommodation Disturbance
Anterior Uveitis
Blepharitis
Conjunctival Hyperemia
Conjunctivitis
Corneal Perforation or Ulcer
Decreased Visual Acuity
Eye Infection
Glaucoma
Increased Intraocular Pressure
Keratitis
Mydriasis
Optic Nerve Damage
Visual Field Defect
Wound Healing Impairment

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle
Shake well before use

Protect from light.

Moxi-Brom (Moxifloxacin/Bromfenac) - Potential Ingredient Risks

(Moxifloxacin hydrochloride 0.5% and Bromfenac sodium sesquihydrate 0.075%)

May be customized.e customized.

Moxifloxacin HCL
(0.5%)

Bromfenac Sodium Sesquihydrate
(0.075%)

Possible Indications

Bacterial Conjunctivitis

Postoperative Ophthalmic Inflammation
Postoperative Ophthalmic Pain

Possible Adverse Effects

Conjunctival Irritation
Decreased Visual Acuity
Dysgeusia
Eye Discharge
Eye Irritation
Eye Pain
Eye Redness
Eyelid Edema
Headache
Increased Lacrimation
Keratitis
Papillary Conjunctivitis
Pyrexia
Subconjunctival Hemorrhage
Tearing
Hypersensitivity Reaction

Abnormal Sensation in Eyes
Anaphylaxis
Anterior Chamber Eye Hemorrhage
Burning Sensation
Conjunctival Hyperemia
Corneal Erosion
Corneal Perforation
Corneal Thinning
Corneal Ulcer
Epithelial Keratopathy
Eye Irritation
Eye Pain
Eye Pruritus
Eye Redness
Headache
Hypersensitivity Reaction
Iritis
Keratitis
Prolonged Bleeding
Stringing Sensation

Potential Contraindications/Precautions

Infants
Lactation
Pregnancy

Lactation
Pregnancy
Pediatric Patients
Corneal Disease
Thrombocytopenia
Rheumatoid Arthritis

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Atropine Sulfate Ophthalmic Solution* - Potential Ingredient Risks

(Atropine Sulfate Ophthalmic Solution 0.01%)

May be customized.

Atropine Sulfate Ophthalmic Solution
(0.01%)

Possible Indications

Widen pupil before an eye exam or eye surgery
Treat eye swelling
Treat amblyopia (lazy eye)
Treat myopia (nearsightedness)

Possible Adverse Effects

Blurred vision
Visual Disturbance
Light sensitivity
Eye stinging, irritation, eye pain
Fast heartbeat
Heartbeat that does not feel normal
Flushing
Restlessness
Feeling irritable
Dry mouth
Dry skin

Potential Contraindications/Precautions

Do not give to children less than 3 months of age
Patients 65 years of age or older, use this preparation with care.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-A* (Azithromycin Ophthalmic Solution) - Potential Ingredient Risks

(Azithromycin Ophthalmic Solution 1%)

May be customized.

Azithromycin Ophthalmic Solution
(1%)

Possible Indications

Bacterial conjunctivitis caused by susceptible bacteria

Possible Adverse Effects

Eye irritation
Blurred vision
Contact dermatitis
Corneal erosion
Decreased visual acuity,
Dysgeusia
Eye pain
Facial edema
Eye reactions: burning sensation, eye discharge, stinging)
Nasal congestion,
Sinusitis
Swelling of the eye
Skin rash

Potential Contraindications/Precautions

Hypersensitivity to Azithromycin or any component of the formulation.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature

20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-B* (Betamethasone Sodium Phosphate Ophthalmic Solution) - Potential Ingredient Risks

(Betamethasone Sodium Phosphate Ophthalmic Solution 0.1%)

May be customized.

Betamethasone Sodium Phosphate Ophthalmic Solution
(0.1%)

Possible Indications

Treat eye irritation
Treat eye swelling

Possible Adverse Effects

Headache
Eye burning, irritation, itching
Dry eyes
Blurred eyesight
Feeling that something is in the eye
Runny nose
Sore throat
Light sensitivity
Cataracts or glaucoma with chronic use
Corneal erosion

Potential Contraindications/Precautions

Infants and children under the age of 18.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-C Drops® (Cyclosporine ophthalmic emulsion) PF - Potential Ingredient Risks

(Cyclosporine ophthalmic emulsion 0.1%)

May be customized.

Cyclosporine ophthalmic emulsion
(0.1%)

Possible Indications

Keratoconjunctivitis Sicca

Possible Adverse Effects

Blurred Vision
Conjunctival Hyperemia
Epiphora
Eye Discharge
Eye Pain
Foreign Body Sensation
Hypersensitivity
Pruritus
Stinging of the eyes
Swelling of the Eyes
Burning Sensation
Urticaria
Visual Disturbance

Potential Contraindications/Precautions

Infants and patients less than 16 years of age
Lactation

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Store upright in original bottle

Klarity-L* (Loteprednol Etabonate Ophthalmic Suspension) - Potential Ingredient Risks

(Loteprednol Etabonate Ophthalmic Suspension 0.5%)

May be customized.

Loteprednol Etabonate Ophthalmic Suspension
(0.5%)

Possible Indications

Treat eye irritation
Treat eye swelling
Treat eye pain after surgery

Possible Adverse Effects

Headache
Eye burning, irritation, itching
Dry eyes
Blurred eyesight
Feeling that something is in the eye
Runny nose
Sore throat
Light sensitivity
Cataracts or glaucoma with chronic use

Potential Contraindications/Precautions

Infants and children under the age of 18.
Pregnant or breast-feeding, talk to your physician prior to use

Storage

Store at Room Temperature
20°C to 25°C (68°F to 77°F)

Auxillary Labeling

Shake well before use.
Store upright in original bottle.

*Available from 503A only.